Marginal Zone Lymphoma
Marginal Zone Lymphoma
The latest news, research, and perspectives in marginal zone lymphoma (MZL).
Patrick DalyMarginal Zone Lymphoma | November 14, 2023
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Read More
Patrick DalyMarginal Zone Lymphoma | November 14, 2023
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
Loretta Nastoupil, MDMeeting News | October 26, 2023
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Loretta Nastoupil, MDVideo Insights | October 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Leah LawrenceMeeting News | September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Cecilia BrownChronic Lymphocytic Leukemia | September 1, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Leah SherwoodChronic Lymphocytic Leukemia | February 8, 2024
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Leah SherwoodMarginal Zone Lymphoma | November 28, 2022
The European Medicines Agency issued a positive opinion recommending approval of zanubrutinib in adults with MZL.
Editorial Board